Health Care • Medical Specialities
$436.00 ▲ +11.58
(+2.73%)
MKT CAP: $62.85B • VOL: 1.33M
52W L $181 52W H $437
NTRA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.31B | $1.70B | $1.08B |
| YoY Revenue Growth % | +35.9% | +56.7% | — |
| Gross Profit | $1.01B | $746.6M | $476.3M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$309.9M | -$222.3M | -$446.2M |
| Operating Margin % | -13.4% | -13.1% | -41.2% |
| Net Income (GAAP) | -$208.2M | -$190.4M | -$434.8M |
| EBITDA (Normalized) | -$225.0M | -$169.2M | -$407.3M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $215.3M | $135.7M | -$247.0M |
| Capital Expenditures (CapEx) | $106.2M | $66.4M | $48.7M |
| Free Cash Flow (FCF) | $109.1M | $69.2M | -$295.7M |
| FCF Margin % | 4.7% | 4.1% | -27.3% |
| Return on Invested Capital (ROIC %) | -13.9% | -14.4% | -1.7% |
| Cash & Short-Term Equivalents | $263.8M | $182.7M | $3.80B |
| Total Debt (Short + Long Term) | $308.7M | $209.4M | $8.09B |
| Total Stockholders' Equity | $1.71B | $1.20B | $16.59B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NTRA.